067630 — HLB Life Science Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual income statement for HLB Life Science Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	53,494	99,591	97,990	102,240	45,752
Cost of Revenue
Gross Profit	-5,537	-3,046	-749	-2,187	-494
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	85,760	134,514	163,499	148,876	70,232
Operating Profit	-32,265	-34,922	-65,508	-46,636	-24,479
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-53,624	-60,839	-6,503	3,149	-100,566
Provision for Income Taxes
Net Income After Taxes	-49,292	-54,360	-5,913	6,207	-99,899
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-49,152	-54,277	-5,983	6,138	-99,794
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-49,152	-54,277	-5,983	6,138	-99,794
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-383	-437	194	180	-788
Dividends per Share